NEW YORK (GenomeWeb News) – Critical Path Institute (C-Path) and The Hamner Institutes for Health Sciences have signed a memorandum of understanding to collaborate on finding markers for monitoring drug-induced liver injury.
The non-profit research organizations plan to collaborate on regulatory science research for predicting, detecting, and monitoring liver safety issues during the development of new medicines. They said a goal of the collaboration is to generate data and reach scientific consensus for biomarkers and other methods that would be submitted to the US Food and Drug Administration to be qualified for specific uses in product development.
"It is imperative that we continue to build important synergies to support cutting-edge research that ultimately translates to getting safer, more effective medicines into the hands of patients," Raymond Woolsey, president and CEO of Tucson, Ariz.-based C-Path.